116 related articles for article (PubMed ID: 16878563)
1. Impact of interseed attenuation and tissue composition for permanent prostate implants.
Carrier JF; Beaulieu L; Therriault-Proulx F; Roy R
Med Phys; 2006 Mar; 33(3):595-604. PubMed ID: 16878563
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
Chibani O; Williamson JF; Todor D
Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
[TBL] [Abstract][Full Text] [Related]
3. Monte Carlo study of LDR seed dosimetry with an application in a clinical brachytherapy breast implant.
Furstoss C; Reniers B; Bertrand MJ; Poon E; Carrier JF; Keller BM; Pignol JP; Beaulieu L; Verhaegen F
Med Phys; 2009 May; 36(5):1848-58. PubMed ID: 19544804
[TBL] [Abstract][Full Text] [Related]
4. A Monte Carlo study on the effect of seed design on the interseed attenuation in permanent prostate implants.
Afsharpour H; D'Amours M; Coté B; Carrier JF; Verhaegen F; Beaulieu L
Med Phys; 2008 Aug; 35(8):3671-81. PubMed ID: 18777927
[TBL] [Abstract][Full Text] [Related]
5. Monte Carlo investigation of I-125 interseed attenuation for standard and thinner seeds in prostate brachytherapy with phantom validation using a MOSFET.
Mason J; Al-Qaisieh B; Bownes P; Henry A; Thwaites D
Med Phys; 2013 Mar; 40(3):031717. PubMed ID: 23464312
[TBL] [Abstract][Full Text] [Related]
6. Investigation of interseed attenuation and tissue composition effects in (125)I seed implant prostate brachytherapy.
Mason J; Al-Qaisieh B; Bownes P; Henry A; Thwaites D
Brachytherapy; 2014; 13(6):603-10. PubMed ID: 24913435
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of low energy brachytherapy Monte Carlo dose calculations to uncertainties in human tissue composition.
Landry G; Reniers B; Murrer L; Lutgens L; Gurp EB; Pignol JP; Keller B; Beaulieu L; Verhaegen F
Med Phys; 2010 Oct; 37(10):5188-98. PubMed ID: 21089752
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of dosimetric effects of metallic artifact reduction and tissue assignment on Monte Carlo dose calculations for
Assam I; Vijande J; Ballester F; Pérez-Calatayud J; Poppe B; Siebert FA
Med Phys; 2022 Sep; 49(9):6195-6208. PubMed ID: 35925023
[TBL] [Abstract][Full Text] [Related]
9. Tissue composition and density impact on the clinical parameters for (125)I prostate implants dosimetry.
Oliveira SM; Teixeira NJ; Fernandes L; Teles P; Vieira G; Vaz P
Phys Med; 2014 Nov; 30(7):799-808. PubMed ID: 25239870
[TBL] [Abstract][Full Text] [Related]
10. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models.
Thomson RM; Rogers DW
Med Phys; 2010 Jan; 37(1):368-76. PubMed ID: 20175499
[TBL] [Abstract][Full Text] [Related]
11. Quantifying the effect of seed orientation in postplanning dosimetry of low-dose-rate prostate brachytherapy.
Collins Fekete CA; Plamondon M; Martin AG; Vigneault É; Verhaegen F; Beaulieu L
Med Phys; 2014 Oct; 41(10):101704. PubMed ID: 25281943
[TBL] [Abstract][Full Text] [Related]
12. MCPI: a sub-minute Monte Carlo dose calculation engine for prostate implants.
Chibani O; Williamson JF
Med Phys; 2005 Dec; 32(12):3688-98. PubMed ID: 16475768
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric and radiobiological investigation of permanent implant prostate brachytherapy based on Monte Carlo calculations.
Haidari AM; Miksys N; Soubiran P; Cygler JE; Holmes O; Perry G; Thomson RM
Brachytherapy; 2019; 18(6):875-882. PubMed ID: 31400953
[TBL] [Abstract][Full Text] [Related]
14. Postimplant dosimetry using a Monte Carlo dose calculation engine: a new clinical standard.
Carrier JF; D'Amours M; Verhaegen F; Reniers B; Martin AG; Vigneault E; Beaulieu L
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1190-8. PubMed ID: 17467924
[TBL] [Abstract][Full Text] [Related]
15. An analytical model to determine interseed attenuation effect in low-dose-rate brachytherapy.
Safigholi H; Sardari D; Karimi Jashni S; Mahdavi SR; Meigooni AS
J Appl Clin Med Phys; 2013 May; 14(3):4226. PubMed ID: 23652254
[TBL] [Abstract][Full Text] [Related]
16. Use of novel thermobrachytherapy seeds for realistic prostate seed implant treatments.
Warrell G; Shvydka D; Parsai EI
Med Phys; 2016 Nov; 43(11):6033. PubMed ID: 27806619
[TBL] [Abstract][Full Text] [Related]
17. An experimental palladium-103 seed (OptiSeedexp) in a biocompatible polymer without a gold marker: characterization of dosimetric parameters including the interseed effect.
Abboud F; Scalliet P; Vynckier S
Med Phys; 2008 Dec; 35(12):5841-50. PubMed ID: 19175140
[TBL] [Abstract][Full Text] [Related]
18. The robustness of dose distributions to displacement and migration of 125I permanent seed implants over a wide range of seed number, activity, and designs.
Beaulieu L; Archambault L; Aubin S; Oral E; Taschereau R; Pouliot J
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1298-308. PubMed ID: 15001275
[TBL] [Abstract][Full Text] [Related]
19. The difference of scoring dose to water or tissues in Monte Carlo dose calculations for low energy brachytherapy photon sources.
Landry G; Reniers B; Pignol JP; Beaulieu L; Verhaegen F
Med Phys; 2011 Mar; 38(3):1526-33. PubMed ID: 21520864
[TBL] [Abstract][Full Text] [Related]
20. Calcifications in low-dose rate prostate seed brachytherapy treatment: post-planning dosimetry and predictive factors.
Collins Fekete CA; Plamondon M; Martin AG; Vigneault É; Verhaegen F; Beaulieu L
Radiother Oncol; 2015 Mar; 114(3):339-44. PubMed ID: 25702862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
